The Relative Strength (RS) Rating for Zai Lab ADR entered a new percentile Tuesday, with an increase from 78 to 82.
Risk Management In The Stock Market: How Much Money To Invest Now
IBD's unique rating tracks price movement with a 1 (worst) to 99 (best) score. The score shows how a stock's price movement over the trailing 52 weeks holds up against all the other stocks in our database.
Decades of market research reveals that the best-performing stocks often have an RS Rating of above 80 as they launch their biggest runs.
Now is not an ideal time to jump in since it isn't near a proper buy zone, but see if the stock goes on to offer and clear a proper buy point.
Zai Lab ADR reported 0% earnings growth in its most recent report, while sales growth came in at 9%.
Zai Lab ADR earns the No. 157 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and Rigel Pharmaceuticals are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
